|
|
||||||||
Departments of 1Pediatrics and 2Environmental Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York; and 3Pulmonary Division, Department of Pediatric Pulmonary, Johns Hopkins School of Medicine, Baltimore, Maryland
Submitted 4 April 2006 ; accepted in final form 10 July 2006
| ABSTRACT |
|---|
|
|
|---|
, a protein expressed by type I cells, with minimal changes detected in genes expressed by vascular cells. These data suggest that perinatal hyperoxia adversely affects alveolar development by disrupting the proper timing of type II cell proliferation and differentiation into type I cells. alveoli; cell proliferation; differentiation; enhanced green fluorescent protein; proliferating cell nuclear antigen
(also known as RTI40), aquaporin-5, caveolin-1, or the cyclin-dependent kinase inhibitor p15 (41, 42). Type II cells, on the other hand, are large, cuboidal cells that contain lamellar bodies and apical microvilli (21). These cells are important for producing surfactant, regulating alveolar fluid levels, and host defense. Type II cells may be identified by their expression of surfactant proteins (SP)-A, SP-B, and SP-C, of which SP-C is expressed solely by type II cells (54). Type II cells are also important progenitor cells for type I cells during lung development and remodeling of injured alveoli. Because in vivo exposure of adult animals to hyperoxia (oxygen >90%) selectively kills alveolar type I cells, it has often been used to study how type II cells participate in alveolar remodeling (3, 16, 26). Although type II cells swell during exposure, frank destruction is not observed by the time mortality occurs. During recovery in room air, type II cells proliferate, and some differentiate into type I cells (2, 51). A similar process occurs in vitro, where freshly isolated type II cells spontaneously lose expression of surfactant genes and gain expression of type I cell-specific markers (17, 48). Although SP expression can be restored by addition of keratinocyte growth factor and culture on Matrigel or floating collagen gels, it is unknown whether such reversible transdifferentiation occurs in vivo. Differentiating type II cells may also contribute to vascular development by their transient expression of vascular endothelial growth factor (VEGF) (30). Although alveolar structure is often restored, abnormal repair and fibrosis can occur when the proliferation of type II cells and fibroblasts becomes unbalanced (4). Fibrosis may be caused by the loss of type II cells, which express antimitogens for fibroblasts (40). Although cultured type II cells isolated from hyperoxic rats undergo apoptosis, extensive type II cell apoptosis after in vivo hyperoxia has yet to be reported (13). Nonetheless, restoration of normal alveolar structure requires proper proliferation and differentiation of type II cells.
Unlike adults that succumb to hyperoxia, newborns are remarkably tolerant and can survive for weeks in fairly high oxygen concentrations. However, hyperoxia disrupts postnatal alveolar development, and this may be a significant cause of bronchopulmonary dysplasia (BPD) seen in premature infants (10). As in infants with BPD, the lungs of newborn rodents exposed to hyperoxia exhibit enlarged, simplified alveoli and overall growth arrest (9, 18, 52). Even brief exposure to hyperoxia followed by recovery in room air permanently disrupts alveolar development (33). Interestingly, low exposures of 0.4 inspired O2 fraction for 6 days followed by recovery in room air were sufficient to permanently retard lung development in newborn rats (12). Despite great efforts by many investigators, it remains unclear how hyperoxia disrupts alveolar development. Because postnatal lung development requires coordinated proliferation and differentiation between epithelial and mesenchymal cells, hyperoxia is likely to disrupt paracrine signaling. Indeed, exogenous VEGF restores alveolar development in newborn rats exposed to hyperoxia for 12 days and recovered in room air for an additional 10 days (28). Consistent with VEGF being a critical regulator of lung development, pharmacological inhibitors of VEGF receptors disrupt alveolar development in mice or rats (29, 34). In addition to disrupting vascular signaling, hyperoxia also inhibits cell proliferation, increases cell death, and promotes inflammation, all of which could contribute to disrupted lung development (6, 20, 35, 44). Despite evidence that hyperoxia disrupts type II cell proliferation and organization in premature baboons (31, 50), little is known about how these cells participate in the abnormal remodeling observed when newborns are recovered in room air.
One of the limitations of studying cell fate during tissue injury is that cell-specific gene expression frequently declines. For example, hyperoxia inhibits expression of pro-SP-B and pro-SP-C that would otherwise be used to identify type II cells in tissue sections (47, 55). For these reasons, we created a line of transgenic mice in which enhanced green fluorescence protein (EGFP) was targeted to type II cells under control of the human SP-C gene promoter (47). We reasoned that the intrinsic green fluorescence of EGFP would be retained longer during hyperoxia because it is not secreted. As hypothesized, type II cells could be identified by their expression of EGFP in adult mice exposed to hyperoxia even when SP-C immunostaining had declined (47). In the present study, these mice were used to investigate type II cell proliferation and alveolar remodeling in adult and newborn mice exposed to hyperoxia. Unlike adult lungs that fully recover from hyperoxia, newborn lungs recovered from hyperoxia display a significant reduction in the number of type II cells along with increased alveolar compliance. Our findings provide new insight into how neonatal hyperoxia permanently disrupts alveolar development.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Immunohistochemistry.
Lungs were inflation fixed with 10% neutral buffered formalin. Lobes were dehydrated in graded ethanol, cleared in xylene, and embedded in paraffin. Paraffin sections (4 µm) were deparaffinized with xylene and rehydrated through graded ethanol and water. BrdU was detected in lung sections with a BrdU staining kit (Zymed Laboratories) with 3,3'-diaminobenzidine as a substrate and methyl green as a counterstain. Sections for proliferating cell nuclear antigen (PCNA) immunostaining were subjected to antigen retrieval by boiling in 50 mM Tris pH 9.5 and incubated overnight in biotinylated anti-PCNA antibody (Zymed), and immune complexes were detected with streptavidin-Texas Red (Jackson Immunoresearch, West Grove, PA). EGFP was detected by visualizing intrinsic green fluorescence or with a fluorophore-conjugated goat anti-EGFP antibody (1:1,000; Novus Biologicals, Littleton, CO). Because antigen retrieval inactivates EGFP fluorescence, pro-SP-B and pro-SP-C were detected with rabbit anti-pro-SP-B (1:1,000) or -pro-SP-C sera (1:10,000; Chemicon International, Temecula CA) and a Tyramide Signal Amplification biotin system. Clara cell secretory protein (CCSP) was detected with rabbit anti-CCSP sera (43, 47). T1
was detected with hamster anti-mouse monoclonal T1
(1:1,000; clone 8.1.1, Iowa Hybridoma Bank). After tissues were immunostained, sections were immersed in 4',6-diamidino-2-phenylindole (DAPI) and visualized with a Nikon E-800 fluorescence microscope (Nikon, Melville, NY). Images were captured with a SPOT-RT digital camera (Diagnostic Instruments, Sterling Heights, MI).
Quantitative immunohistochemistry. Images of random, noncontiguous fields of parenchyma were acquired with a Nikon E-800 microscope equipped with a SPOT-RT camera. Five fields per lung were obtained from at least three separate animals for each treatment. Fields that contained a large airway or blood vessel were rejected. For counting BrdU-positive cells, regions were selected under bright-field illumination. For counting fluorescence-positive cells, regions were selected under DAPI fluorescence to prevent bias toward fields with FITC or Texas Red signals. Different fluorescent filters were used to acquire images of each field displaying nuclei (DAPI), PCNA or pro-SP-C (Texas Red), and pro-SP-B or EGFP (FITC). Images were digitally merged to identify dual-positive cells. Quantification was performed with Metamorph software (Universal Imaging, Downingtown, PA). Metamorph was configured to measure total nuclei based on the average number of pixels in a nucleus. For each animal, the counts from all fields were summed and the following ratios were determined: BrdU positive/nuclei, pro-SP-B positive/DAPI positive, EGFP positive/DAPI positive, pro-SP-C positive/DAPI positive, PCNA positive/DAPI positive, PCNA positive/pro-SP-B positive, and PCNA positive/EGFP positive cells. The ratios for all animals at each time point were averaged and graphed.
Western blots.
Tissues were homogenized in lysis buffer containing protease inhibitors (38). Proteins were separated on polyacrylamide gels and transferred to polyvinylidene fluoride membranes. Membranes were blocked in 5% nonfat dry milk before incubating overnight at 4°C in anti-EGFP (1:1,000; Clontech, Palo Alto, CA), anti-pro-SP-C (1:1,000; Santa Cruz Biotechnology), anti-platelet endothelial cell adhesion molecule (PECAM) (1:1,000; Santa Cruz Biotechnology), anti-T1
(1:2,000; Iowa Hybridoma Bank), or
-actin (1:1,000; Sigma, St. Louis, MO) sera. Immune complexes were detected by chemiluminescence (Amersham, Arlington Heights, IL) and visualized by exposure to Kodak Bio-Max film. Images were captured on a FluorChem SP (Alpha Innotech, San Leandro, CA), and band intensities were quantified.
RNase protection assays. Total RNA was prepared from lung homogenates with TRIzol (Invitrogen). Radiolabeled RNA probes encoding Flt1, Flt4, Tie1, Tie2, CD31, VEGF, endoglin, and L32 were synthesized at room temperature according to the RiboQuant Multi-Probe RNase Protection Assay System (PharMingen, San Diego, CA), hybridized to 10 µg of total RNA, and processed according to the kit (37). Protected RNAs obtained after RNase digestion were ethanol precipitated and separated on a 6% polyacrylamide gel. The gel was dried and exposed to a PhosphoImage screen for visualization. Band intensities were normalized to L32 and quantified with ImageQuant analysis.
Statistical analysis. Values are expressed as means ± SD unless noted. Group means were compared by ANOVA with Fisher's procedure for post hoc analysis, and P < 0.05 was considered significant.
| RESULTS |
|---|
|
|
|---|
|
|
Type II cells are reduced in newborn mice recovered from hyperoxia. Because alveolar development is permanently disrupted in newborn mice recovered from hyperoxia, the effects of hyperoxia on type II cell proliferation were investigated. Newborn mice were exposed to hyperoxia from postnatal day 1 to postnatal day 4 and then recovered in room air for up to 8 wk. To ensure that outcomes were not attributed to differences in maternal care, mothers were rotated between pups exposed to room air and hyperoxia. Despite this, the average weight of newborn mice recovered from hyperoxia for 1 and 2 wk was 50% and 25% less, respectively, than that of their siblings exposed to room air (n = 70; P < 0.001). By 4 wk of recovery, animal weights were not significantly different. At 8 wk of age, the average weight of mice exposed to room air was 21.8 ± 2.1 g vs. 20.2 ± 2.6 g for mice exposed to and recovered from hyperoxia (n = 18; P = 0.23). These data are consistent with studies showing that newborn exposure to hyperoxia inhibits cell proliferation and overall animal growth, which returns to control levels during recovery in room air (33).
Surprisingly, adult lungs previously exposed to hyperoxia as newborns contained few EGFP-positive type II cells (Fig. 3A). Moreover, fluorescence intensity was less in positive cells. To identify when hyperoxia reduced the number of type II cells, the proportion of EGFP-positive cells was quantified. The proportion of EGFP-positive cells was very low at birth and progressively increased with age, reaching a maximum of 6% by 6 wk before slightly declining at 8 wk. In newborns exposed to hyperoxia, the proportion of EGFP-positive cells was not different until the second week of recovery, at which time it failed to increase at the same rate as room air controls. Because intrinsic green fluorescence intensity was also less in mice recovered from hyperoxia, there was concern that faint green type II cells were not being counted. To amplify the EGFP signal such that all positive cells exhibited the same fluorescence intensity, sections were stained with an anti-EGFP antibody that was detected with Texas Red-conjugated secondary antibodies. The total numbers of intrinsic green EGFP- and red immunostained EGFP-positive cells were quantified and found to be not significantly different.
|
4% at birth and progressively increased with age until 2530% of alveolar cells were pro-SP-B positive in adults (Fig. 3B). In newborn mice recovering from hyperoxia, the number of pro-SP-B-positive cells increased at a slower rate beginning at 2 wk of age and remained low through adulthood.
The expression of pro-SP-C was also investigated because its expression is restricted to type II cells. Because of high background staining in newborn mice, we were only able to quantify pro-SP-C-positive cells in adult lungs. Like EGFP and pro-SP-B, the number and staining intensity of pro-SP-C-positive cells were significantly less in adult mice recovered from newborn hyperoxia (Fig. 4A). Pro-SP-C was detected in 20.7 ± 5.1 cells of 8-wk-old mice exposed to room air vs. 14.2 ± 3.3 cells of mice recovered from newborn hyperoxia (P < 0.001). Despite fewer type II cells in recovered mice, the total number of DAPI-positive cells counted was not significantly different (P = 0.34). This suggested that hyperoxia may have stimulated the differentiation of type II cells into type I cells rather than simply killing off type II cells. Consistent with this hypothesis, alveolar staining of T1
, a gene expressed by type I cells, was markedly elevated in adult mice that had been exposed to hyperoxia as newborns (Fig. 4B). Moreover, <1% of alveolar cells exhibited terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining during postnatal lung development, and this low level of apoptosis was not increased after exposure to hyperoxia (data not shown).
|
. Quantitative analysis of band intensities confirmed that recovered mice expressed fold changes of 2.86 ± 0.55 (P < 0.007) of T1
, 0.65 ± 0.09 (P < 0.008) of EGFP, and 0.23 ± 0.04 (P < 0.00005) of pro-SP-C compared with unexposed controls. Because type II cells are a significant source of VEGF, an important mitogen for vascular development, the expression of vascular-specific proteins was also investigated. Surprisingly, the expression of PECAM was not different (P < 0.38). Likewise, mRNA expression of the vascular genes Flt1, Flt4, Tie1, Tie2, thrombin receptor (TR), PECAM, endoglin, or VEGF was not significantly different between the mice (Fig. 5B). VEGF protein was detected in airway epithelial and alveolar type II cells by immunostaining (data not shown). Because staining intensity was comparable between adult mice exposed to room air versus recovered from hyperoxia, it is unlikely that fewer type II cells compensated by expressing more VEGF.
|
1% was reached at 4 wk of age (Fig. 6A). Cell proliferation was significantly inhibited in postnatal day 4 mice exposed to hyperoxia. However, it markedly increased at 1 wk of recovery and then declined until it reached a steady state of
0.5% at 6 wk of age. This low level of cell proliferation was significantly less than that detected in mice exposed to room air.
|
Hyperoxia permanently disrupts alveolar function in newborn mice. Because adult mice that were exposed to hyperoxia as newborns had fewer type II cells, pulmonary function tests were performed to see whether these changes affected lung physiology (Fig. 7A). Although airway resistance was lower in recovered mice, the difference did not reach statistical significance (P = 0.16). In contrast, alveolar compliance was significantly higher by 30% (P < 0.004). Increased compliance is indicative of larger alveoli, which was significantly elevated in adults that had been exposed to hyperoxia as newborns (33). To confirm that these changes were attributed to newborn exposure to hyperoxia, airway resistance and alveolar compliance were measured in adult mice that had been exposed to and recovered from hyperoxia as adults (Fig. 7B). Unlike newborn exposure, adult exposure to hyperoxia did not alter airway resistance or alveolar compliance (P < 0.83 for both analyses).
|
| DISCUSSION |
|---|
|
|
|---|
, and increased alveolar compliance, indicative of alveolar simplification (12, 33). Our findings emphasize the importance of type II cell proliferation in alveolarization and remodeling, which, when disrupted by hyperoxia, is associated with long-term deficits in lung development.
Our study using PCNA to identify proliferating cells confirms previous studies in which dividing cells were labeled with tritiated thymidine and counted under transmission electron microscopy. The adult mouse lung has a low mitotic index of 2%, of which
50% are leukocytes, 30% endothelial cells, 10% type II epithelial cells, and the remainder interstitial cells (11, 23). Endothelial cells had a turnover of 7 days, whereas type II epithelial cells had a turnover of 4 wk. This low labeling index declines during hyperoxia (24, 50). Inhibition of different cell populations is dependent on the amount of oxygen, with endothelial cells being the most sensitive and type II cells being more resistant (24). Type II cells incorporate tritiated thymidine during recovery, which can then be chased into type I cells as they differentiate (3). In the present study, proliferating type II cells were identified by their expression of PCNA and EGFP or PCNA and pro-SP-B in adult mice recovering from hyperoxia. Presumably, many of these cells differentiated into type I cells or were culled by apoptosis, as the total number of type II cells returned to unexposed levels by 8 wk of recovery.
Unlike adults, newborns exhibit a high proliferative index at birth that slowly declines over the first 2 wk of life. Tritiated thymidine studies in newborn rats reveal that the proliferative index of the vascular endothelium starts high at birth and decreases after 10 days (27). Likewise, fibroblast proliferation is high at birth and slowly subsides by 10 days. In contrast, type II epithelial cell proliferation starts low and markedly increases over 7 days before subsiding by postnatal day 21. During this period, type II cell differentiation into type I cells and final alveolar septation take place. Exposure to >90% oxygen disrupts this process. During the first 72 h, hyperoxia reduces tritiated thymidine or BrdU uptake (36, 52). Although the affected cells were not identified, our study now reveals that type II cell proliferation is inhibited by hyperoxia. Despite the resumption of proliferation at recovery in room air, maximal type II cell proliferation was observed on postnatal day 14, a developmental window when type II cell proliferation normally declines. Hypothetically, proliferating type II cells were now exposed to a microenvironment rich in developmental signals that accelerated their differentiation into type I cells or failed to maintain progenitor populations of type II cells. Consistent with this hypothesis, recovered lungs had proportionally fewer type II cells, expressed higher levels of T1
, a gene expressed by type I cells, and had increased alveolar compliance. Given the proportional loss of type II cells and the potential for less surfactant, increased alveolar compliance is indicative of alveolar simplification, which we (data not shown and Ref. 33) and others (9, 12, 18) have found by measuring mean linear intercept. Because proportionally fewer type II cells are also seen in humans with emphysema (39), our findings suggest that type II cells may play an important role in preventing alveolar simplification.
A number of studies suggest that alveolar development is closely coordinated with growth of the pulmonary circulation. For example, exposure of adult rabbits or mice to hyperoxia reduces expression of VEGF (8, 53). Likewise, expression of VEGF and VEGF receptor Flt-1 declined in premature baboons and human infants that developed chronic lung disease attributed to high oxygen exposure (8, 32). Consistent with the concept that loss of VEGF contributes to the inhibition of alveolar development, normal alveolar development could be restored in hyperoxic newborn rats by providing VEGF exogenously (28). Conversely, treatment of newborn rats with the VEGF receptor inhibitors SU-5416 or DC-101 decreased alveolarization and vascular growth (29, 34). These data collectively support the "vascular hypothesis" concept in which impaired VEGF signaling contributes to the pathogenesis of lung disease such as BPD (1). Because type II cells are a significant source of VEGF, their loss as shown in the present study helps explain how VEGF levels decline during hyperoxia and why exogenous VEGF is efficacious. The mechanisms by which VEGF protects the developing lung against hyperoxia remain to be clarified. VEGF is clearly an important prosurvival and vascular-specific mitogen for endothelial cells, which express VEGF receptors Flt-1 and Flk-1. Because endothelial cells are highly sensitive to oxidant stress, the loss of VEGF may contribute to their susceptibility to hyperoxia. However, type II cells may also express Flk-1, and VEGF has been shown to stimulate SP-B and SP-C expression (15). Although a direct role of VEGF signaling on type II cells remains to be confirmed, attenuating VEGF signaling in lung renal capsule grafts significantly affects lung epithelial cell development (57). Thus VEGF is clearly important for both endothelial and epithelial cell growth and survival.
Given the importance of vascular cells for lung development, it was surprising not to detect permanent changes in vascular-specific genes in adult mice recovered from newborn hyperoxia. It does not appear from immunohistochemical staining that type II cells in recovered adult mice compensated by expressing more VEGF (data not shown). As shown in the Western blot in Fig. 5 and as defined by immunohistochemical staining, PECAM (CD31) levels were also not different (data not shown). Although additional studies using transmission electron microscopy are needed to quantify endothelial cells, these data collectively suggest that the number of endothelial cells may be similar in recovered mice. One trivial explanation for why vascular genes appear to be less affected than reported in animal models of BPD is that our newborn mice were exposed to 4 days of hyperoxia, which is relatively short compared with other newborn animal models. Indeed, disrupted vascular development was observed in infants that had died, in part, from their exposure to prolonged hyperoxia. Consistent with this hypothesis, expression of VEGF mRNA was unaltered in newborn mice exposed to hyperoxia for 4 days (data not shown). Additionally, mice were recovered in room air for 8 wk, which is relatively long compared with other recovery models. Considering the importance of the vasculature for lung development, it will be important to investigate further the role of VEGF and other vascular-specific signaling pathways during this recovery period.
The loss of type II cells in newborn mice recovered from hyperoxia may help clarify why infants who survive BPD often return as children with respiratory problems. BPD is the most common form of chronic lung disease in the newborn and is frequently seen in premature infants with very low birth weight (22). The lungs of these infants are less vascularized, and alveoli are fewer and larger. Because premature infants have low plasma levels of glutathione and develop BPD when exposed to hyperoxia and ventilation, it is generally accepted that BPD is caused largely by oxidative stress to the developing lung (49). If we can extrapolate our findings with BPD, the inability of type II cells to proliferate during the first week of life may permanently alter postnatal lung growth during a critical period of postnatal lung development. For those who survive BPD, the long-term detrimental effects of oxidative stress in the neonatal period are just beginning to be appreciated. Sadly, survivors exhibit increased airway resistance and reduced lung capacity later in life (45). These changes have even been reported in children as old as 810 yr of age (5). Clinical studies reveal that exposure to oxygen in the neonatal period is associated with permanent narrowing of small airways (14). Perhaps one of the most compelling arguments that oxidative stress can alter human lung development comes from clinical studies in which premature infants instilled with recombinant CuZn superoxide dismutase had improved pulmonary function at 1 yr of corrected age (19). In the present study, newborn exposure to hyperoxia did not significantly alter airway resistance or morphology in recovered adult mice. A trivial explanation is that airways of premature infants are at a different stage of development than those of normal newborn mice. In other words, premature airways may be more sensitive to oxidative stress than term airways. Alternatively, recovered mice might have outgrown an airway deficit that would have been seen at an earlier age. Nonetheless, our finding that recovered mice have fewer type II cells suggests that similar losses may be taking place in conducting airways, particularly in premature humans who are already sensitive to oxidative stress.
There are several limitations to this study. First, adult mice were exposed to hyperoxia for 64 h, whereas newborns were exposed for 4 days. The differences seen in lung remodeling are unlikely to be caused by the length of exposure or the degree of lung injury. Even though adults recover, they are more injured after 64 h of hyperoxia than newborns exposed for 4 days. Second, type II cells were quantified based on their expression of EGFP, pro-SP-B, or pro-SP-C. Although less staining was interpreted as fewer cells, it remains possible that individual type II cells simply express less protein that could not be detected and thus the total number of type II cells is actually unchanged. At this time, our data cannot dispute the possibility that the total number of type II cells in the entire lung is unchanged. The use of three independent markers for type II cells, the compensatory increase in expression of the type I cell specific protein T1
, and the fact that the total number of cells counted was not different between the mice makes this seem unlikely. Clearly, morphometric counts of type I cells by transmission electron microscopy are needed to confirm that recovered lungs have more type I cells. Although we did not detect increased TUNEL staining, we cannot rule out that apoptosis may also contribute to the reduced numbers of type II cells seen in recovered mice. Indeed, increased TUNEL staining has been seen in newborn mice exposed to hyperoxia, and freshly isolated embryonic mouse type II cells apoptose when exposed to hyperoxia (7, 20, 35). Because TUNEL staining may reflect oxidative DNA strand breaks and not necessarily apoptosis (7, 46), additional studies are needed to clarify the fate of type II cells in these recovered mice. Finally, the thin morphology of microvascular endothelial and type I epithelial cells makes them difficult to quantify. Although differences in T1
expression were readily detected, it remains possible that recovered lungs have subtle changes in microvascular cells that cannot be detected by analyzing the entire lung.
In summary, short-term exposure of newborn mice to hyperoxia permanently disrupts alveolar development as defined by a proportional loss in the number of type II cells and increased alveolar compliance possibly caused by compensatory increase in the number of type I cells. These effects are attributed to a temporal shift in type II cell proliferation from postnatal day 7 to day 14. In light of these findings, we speculate that this shift causes type II cells to be proliferating in an environment that now favors or accelerates their differentiation to type I cells. This disruption in alveolar epithelial cell differentiation might contribute to the pathological processes seen in infants with BPD and perhaps adults who develop emphysema and chronic obstructive pulmonary disease.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
antisera, and Rick Watkins for advice on fluorescent immunohistochemistry. | FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. A. O'Reilly, S. H. Marr, M. Yee, S. A. McGrath-Morrow, and B. P. Lawrence Neonatal Hyperoxia Enhances the Inflammatory Response in Adult Mice Infected with Influenza A Virus Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1103 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Balansky, G. Ganchev, M. Iltcheva, V. E. Steele, F. D'Agostini, and S. De Flora Potent carcinogenicity of cigarette smoke in mice exposed early in life Carcinogenesis, October 1, 2007; 28(10): 2236 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Auten, S. N. Mason, M. H. Whorton, W. R. Lampe, W. M. Foster, R. N. Goldberg, B. Li, J. S. Stamler, and K. M. Auten Inhaled Ethyl Nitrite Prevents Hyperoxia-impaired Postnatal Alveolar Development in Newborn Rats Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 291 - 299. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Reddy, S. R. Kleeberger, H.-Y. Cho, M. Yamamoto, T. W. Kensler, S. Biswal, and S. P. Reddy Deficiency in Nrf2-GSH Signaling Impairs Type II Cell Growth and Enhances Sensitivity to Oxidants Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 3 - 8. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||